Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity: The result of the ACCEL-DIP study

Thrombosis and Haemostasis

Volumn 112, Issue 6, 2014, Pages 1198-1208

  Park, Yongwhi ^a   Jeong, Young Hoon ^a   Tantry, Udaya S ^b   Ahn, Jong Hwa ^a   Kim, Kye Hwan ^a   Koh, Jin Sin ^a   Park, Jeong Rang ^a   Hwang, Seok Jae ^a   Kwak, Choong Hwan ^a   Hwang, Jin Yong ^a   Gurbel, Paul A ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Clopidogrel; Dipyridamole; Intervention; Platelets

Indexed keywords

ABCB1 PROTEIN, HUMAN; ACETYLSALICYLIC ACID; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; DIPYRIDAMOLE; MULTIDRUG RESISTANCE PROTEIN; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOPROTEIN; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; DEVICES; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; STENT; THROMBOCYTE; THROMBOCYTE AGGREGATION; TIME; TREATMENT OUTCOME;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP3A; DIPYRIDAMOLE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; P-GLYCOPROTEINS; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84914124871     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-01-0040     Document Type: Article

References (43)

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44–122.
2. Tantry US, Bonello L, Aradi D, et al.; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
5. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010; 121: 569-583.
6. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 2010; 55: 1671-1678.
7. Tricoci P, Huang Z, Held C, et al.; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20–33.
8. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19.
9. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-646.
10. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
11. Han Y, Li Y, Wang S, Jing Q, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-739.
12. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
13. Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011; 4: 381-391.
14. Jang JS, Jin HY, Seo JS, et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 2012; 122: 133-143.
15. Ueno M, Ferreiro JL, Tomasello SD, et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc Interv 2011; 4: 905-912.
16. Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39–42.
17. Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol 2010; 9: 273-284.
18. Malloy RJ, Kanaan AO, Silva MA, et al. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. Clin Ther 2013; 35: 1490–1500.e7.
19. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39: 1358-1363.
20. Liu Y, Cone J, Le SN, et al. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. J Cardiovasc Pharmacol 2004; 44: 266-273.
21. Kim IS, Jeong YH, Tantry US, et al. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. Am Heart J 2013; 166: 95–103.
22. Park Y, Jeong YH, Tantry US, et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J 2012; 33: 2151-2162.
23. Jeong YH, Bliden KP, Tantry US, Gurbel PA. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost 2012; 10: 487-489.
24. Angiolillo DJ, Bernardo E, Zanoni M, et al. Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2011; 58: 30-39.
25. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91: 651-690.
26. Rondina MT, Weyrich AS. Targeting phosphodiesterases in anti-platelet therapy. Handb Exp Pharmacol 2012; 210: 225-238.
27. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488–520.
28. Aktas B, Utz A, Hoenig-Liedl P, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signalling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34: 764-769.
29. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e89S-119S.
30. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2007; 3: CD001820.
31. Picano E;PISA (Persantin In Stable Angina) study group. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. Eur Heart J 2001; 22: 1785-1793.
32. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013; 7: CD003464.
33. Magnusson M, Gunnarsson M, Berntorp E, et al. Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol 2008; 581: 290-295.
34. Smolenski A. Novel roles of cAMP/cGMP-dependent signalling in platelets. J Thromb Haemost 2012; 10: 167-176.
35. Jeong YH. Clopidogrel with aspirin in minor stroke or transient ischaemic attack. N Engl J Med 2013; 369: 1376.
36. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischaemic attack. N Engl J Med 2013; 369: 11-19.
37. Bath PM. Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (TARDIS). Available at: http://clinicaltrials.gov/show/NCT01661322. Accessed January 5, 2014.
38. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60: 193-199.
39. Jeong YH, Kim IS, Park Y, et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010; 3: 731-741.
40. Zhang ZY, Chen M, Chen J, et al. Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate. J Pharm Biomed Anal 2009; 50: 200-209.
41. Halkes PH, van Gijn J, Kappelle LJ, et al.; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
42. Sacco RL, Diener HC, Yusuf S, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
43. Nijjer SS, Davies JE, Francis D P. Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENTOASIS-7, TRITON-TIMI-38 and PLATO. Int J Cardiol 2012; 158: 181-185.